Articles tagged with: ARRY-520


[ by and | Dec 24, 2013 11:47 am | One Comment ]
Filanesib (ARRY-520) Continues To Show Promise In Heavily Pretreated Multiple Myeloma Patients (ASH 2013)

Results from three clinical trials involving the investigational drug filanesib were presented at the American Society of Hematology (ASH) annual meeting earlier this month.

The trials evaluated the efficacy of filanesib (ARRY-520) alone and in com­bi­na­tion with other agents as potential treatments for relapsed and refractory multiple myeloma patients.

Overall, the trial results presented at ASH confirm existing impressions of filanesib as a promising potential myeloma therapy.

Results of a Phase 2 trial of filanesib with or without low-dose dex­a­meth­a­sone (Decadron) show that 16 percent of …

Read the full story »


[ by | Dec 13, 2013 9:16 pm | 3 Comments ]
ASH 2013 Multiple Myeloma Update - Day Three: Morning Oral Sessions

This Monday was the third day of the 2013 American Society of Hema­tol­o­gy (ASH) annual meeting, which was held in New Orleans.

More than any other day of the conference, Monday was packed with im­por­tant myeloma presentations, from 7:00 in the morning until almost 8:00 in the eve­ning.

This ASH update will summarize the oral presentation sessions about treat­ment-related myeloma studies that were held Monday morning. An ASH update that was published on Wednesday focused on the sessions that were held Monday afternoon and evening.

Monday morning started with …

Read the full story »


[ by | Dec 8, 2013 5:16 pm | 4 Comments ]
ASH 2013 Multiple Myeloma Update - Day One

This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.

Myeloma-related presentations were made during several sessions yesterday.

Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.

The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.

During the session, research results were made available for review by meeting attendees in …

Read the full story »


[ by | Nov 20, 2013 8:53 pm | 3 Comments ]
ASH 2013 Preview: Treatments In Mid- To Late-Stage Clinical Development For Multiple Myeloma

The Beacon continues today with its ‘ASH preview’ series about mye­lo­ma re­search that will be pre­sented at the American Society of Hema­tol­o­gy (ASH) meet­ing in early December.

Abstracts for the ASH presentations are now available, although many contain pre­lim­i­nary information that will be updated at the meet­ing.

The Beacon’s ASH preview articles are intended to highlight the meet­ing's most interesting myeloma-related studies.

The first and second previews, published earlier this week and last week, provide an overview of ASH abstracts about the newest potential mye­lo­ma therapies just starting out in clinical trials.  Further …

Read the full story »


[ by | Updated: Jun 19, 2013 11:10 pm | Comments Off ]
The European Hematology Association’s Annual Congress Starts Today: A Look At The Key Myeloma-Related Presentations (EHA 2013)

Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year.  The first education and poster sessions of the meet­ing will take place tomorrow, Friday, June 14.  Additional sessions of vari­ous kinds are scheduled for both days of the weekend, until the meet­ing ends early Sunday afternoon (European time).

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related dis­eases, in­clud­ing multiple myeloma.

The EHA …

Read the full story »